MH
MHUAF
Meihua International Medical Technologies Co., Ltd.
$8.30
0.00%
No data for this timeframe.
Vol
SEC Reports2
Exchange OTC·Sector Surgical & Medical Instruments & Apparatus·Inc. E9·CIK 0001835615·Prev Close $8.30
Recent Activity
Apr 29, 2026
SEC
Meihua International's FY2025 annual report reveals a 36% revenue decline to $61.79M and a 37% net income drop to $6.78M
20-F — Impact 8/10
Feb 27, 2026
SEC
Meihua International Medical Technologies Co., Ltd. (MHUAF) has received an effectiveness notice from the SEC for its Fo
EFFECT — Impact 4/10
Latest Reports
BEARISH
20-F
8/10
Meihua International's FY2025 annual report reveals a 36% revenue decline to $61.79M and a 37% net income drop to $6.78M
Apr 29, 2026
NEUTRAL
EFFECT
4/10
Meihua International Medical Technologies Co., Ltd. (MHUAF) has received an effectiveness notice from the SEC for its Fo
Feb 27, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.